Key Takeaways
A securities class-action lawsuit was filed against Aldeyra Therapeutics Inc. after its stock collapsed 71 percent following the rejection of its lead drug candidate by U.S. regulators.
The Complete Response Letter from the Food and Drug Administration stated there is “a lack of substantial evidence” and that “the application has failed to demonstrate efficacy in adequate and well controlled studies," according to a company filing on March 17, 2026.
The lawsuit alleges Aldeyra made materially false and misleading statements between November 3, 2023, and March 16, 2026. On the day of the announcement, Aldeyra's shares dropped by $2.99 to close at $1.24. The FDA's letter noted that the "inconsistency of study results raises serious concerns about the reliability and meaningfulness of the positive findings."
The legal action exposes Aldeyra to significant financial and legal risks, further compounding the loss of investor confidence after the failure of its lead drug candidate. Investors who wish to serve as lead plaintiff have until May 29, 2026, to file with the court.
The rejection of reproxalap and the subsequent lawsuit cast serious doubt on Aldeyra's near-term revenue prospects and the viability of its drug pipeline. The stock's sharp decline to a multi-year low reflects the market's reassessment of the company's value without its lead candidate. Aldeyra's next catalyst will likely be its response to the lawsuit and any updates on its remaining clinical programs.
This article is for informational purposes only and does not constitute investment advice.
